Preterm birth is defined as delivery occurring before 37 weeks' gestation and is a major cause of morbidity and mortality.^[@bibr1-2329048X18800566]^ Neurodevelopmental disabilities associated with prematurity include cerebral palsy,^[@bibr2-2329048X18800566]^ intellectual disability,^[@bibr3-2329048X18800566]^ and autism spectrum disorder.^[@bibr4-2329048X18800566]^ Although each represents distinct areas of disability, all 3 disorders may cooccur. Intellectual impairment affects cognitive functioning; cerebral palsy presents with delayed motor milestones and abnormal muscle tone^[@bibr2-2329048X18800566]^; and autism spectrum disorder is characterized by social communication impairment and repetitive, nonfunctional behaviors and routines.^[@bibr5-2329048X18800566]^ Cerebral palsy in children born prematurely is most commonly associated with periventricular white matter injury,^[@bibr6-2329048X18800566]^ but autism spectrum disorder's pathophysiology among children born preterm is more elusive and complex. Further, while not associated with periventricular injury, children with cerebral palsy are at higher risk for developing autism spectrum disorder, with a prevalence of autism spectrum disorder among children with cerebral palsy estimated at 7%.^[@bibr7-2329048X18800566]^

Interventions in the peri- and neonatal period can reduce some complications of preterm birth. Maternal antenatal steroids and infant surfactant administration attenuate respiratory distress syndrome and hyaline membrane disease^[@bibr8-2329048X18800566]^ (although postnatal steroid administration may worsen neurodevelopmental outcome \[Doyle et al, 2014\]),^[@bibr9-2329048X18800566]^ antibiotics treat infection, and temperature, fluid, and electrolyte management prevent hypothermia and dehydration.^[@bibr10-2329048X18800566]^ With the exception of erythropoietin,^[@bibr11-2329048X18800566]^ there are no treatments in premature infants for the long-term neurological sequelae of prematurity.

However, antenatal magnesium administration to women in preterm labor has demonstrated a modest protective effect against cerebral palsy when provided immediately before birth.^[@bibr12-2329048X18800566],[@bibr13-2329048X18800566]^ The American College of Obstetricians and Gynecologists recommends the administration of antenatal magnesium to mothers facing imminent delivery between 24 and 31 6/7 weeks' gestation.^[@bibr14-2329048X18800566]^ Serum magnesium levels in newborns track closely with maternal serum magnesium levels at the end of pregnancy for neonates both exposed and not exposed to magnesium supplementation.^[@bibr15-2329048X18800566]^ In neonates born from mothers not supplemented with antenatal magnesium, infant magnesium levels have been found to decrease with increasing gestational age.^[@bibr16-2329048X18800566][@bibr17-2329048X18800566][@bibr18-2329048X18800566]--[@bibr19-2329048X18800566]^ Less is known about how magnesium levels vary with gestational age among neonates exposed to maternal antenatal magnesium supplementation or how serum magnesium level variation among neonates corresponds with the magnitude of cerebral palsy risk reduction. Evidence is sparse and results are mixed in regard to the protective effect conferred by neonates' innate magnesium level against cerebral palsy.^[@bibr20-2329048X18800566],[@bibr21-2329048X18800566]^ Magnesium may provide neuroprotection by several possible mechanisms, including reducing brain injury from hypoxic ischemic events by blocking N-methyl-D-aspartic acid receptors and reducing calcium influx into neuronal cells,^[@bibr22-2329048X18800566]^ attenuating cell damage from free radical activity and inflammatory cytokines,^[@bibr22-2329048X18800566]^ and restoring normal axon connection development disrupted by hypoxia.^[@bibr23-2329048X18800566]^

To our knowledge, no prior studies have investigated the potential influence of neonatal magnesium levels on long-term autism spectrum disorder risk among children born preterm. The objective of the current study was to investigate the association between innate neonatal magnesium levels immediately following birth and autism spectrum disorder risk among a large cohort of children born before 37 weeks' gestation.

Methods {#section1-2329048X18800566}
=======

Study Site and Population {#section2-2329048X18800566}
-------------------------

Eligible infants were born \<37 weeks' gestation at an Intermountain Healthcare facility in Utah in calendar years 2002 to 2010. Intermountain Healthcare is a vertically integrated, not-for-profit healthcare system in the Intermountain West encompassing 23 hospitals including the region's only children's hospital. Utah's ethnic distribution is predominantly white, non-Hispanic (79%)^[@bibr24-2329048X18800566]^; Utah's prematurity rate (9.1%) is similar to the national average (9.6%).^[@bibr25-2329048X18800566]^ Inclusion criteria required that infants link to (1) maternal medical records, and have records for (2) birthweight and (3) magnesium level(s) (mg/dL) drawn 24 to 48 hours following birth. Exclusion criteria were the presence of known/likely genetic disorders, congenital hydrocephalus/brain malformations, epileptic encephalopathies, congenital heart disease, meningitis, encephalitis, stroke, traumatic head injury, or death.

Magnesium Exposure and Covariates {#section3-2329048X18800566}
---------------------------------

The first magnesium level drawn 24 to 48 hours following birth was chosen as the exposure of interest to (1) minimize the influence of maternal magnesium administration on measured levels and (2) maximize the number of preterm neonates with available magnesium levels, as levels were inconsistently drawn after 48 hours following birth. Pre/perinatal characteristics and maternal medical comorbidities obtained from the Intermountain Healthcare Enterprise Data Warehouse were as follows: date of birth, sex, race/ethnicity, birthweight, gestational age, 5-minute Apgar score, maternal diabetes (preexisting or gestational), maternal Medicaid insurance, and antenatal maternal magnesium administration. Normalized growth curves^[@bibr26-2329048X18800566]^ were used to stratify size for gestational age with 3 levels: small (birthweight \<10th percentile), average, and large (birthweight \>90th percentile) for gestational age.

Autism Spectrum Disorder Case Identification {#section4-2329048X18800566}
--------------------------------------------

Autism spectrum disorder case status was determined through linkage of the preterm cohort to the Utah Registry of Autism and Developmental Disabilities, a population-wide autism spectrum disorder surveillance system that identifies persons with ASD primarily using an administrative record approach inclusive of education and health sources.^[@bibr27-2329048X18800566]^ Autism spectrum disorder is a reportable health condition under Utah Health Code Chapter 26 Title 7 Section 4. Utah Registry of Autism and Developmental Disabilities is designated by the Utah Department of Health to maintain a registry of individuals who have received autism spectrum disorder--specific diagnostic codes (ie, *International Classification of Diseases, Ninth Revision* 299\*). As part of a longstanding collaboration, the Utah State Board of Education provides information on children eligible for autism special education services. Utah Registry of Autism and Developmental Disabilities identifies a child with autism spectrum disorder based on receipt of an autism spectrum disorder medical diagnosis from a qualified provider and/or a Utah State Board of Education autism special education report. Autism spectrum disorder case status was ascertained through 2014 for the 2002 to 2010 birth cohorts.

Statistical Analyses {#section5-2329048X18800566}
--------------------

Wilcoxon signed-rank, Student *t*, and χ^2^ tests were used to compare children's characteristics with and without autism spectrum disorder. For evaluation of the relationship between neonatal magnesium level and autism spectrum disorder risk, a method similar to that of Ostrander et al^[@bibr21-2329048X18800566]^ was used: Discrete proportional hazards regression models were fit using generalized estimating equations with logarithmic link functions and a working independent correlation structure. Further, the age of autism spectrum disorder, diagnosis was related to neonatal magnesium level with separate binary indicator variables for a positive diagnosis defined for the following age intervals: birth to age 3, age 4 through age 6, and age 7 or older. By defining that autism spectrum disorder is present or absent at birth, and assuming that the age at which autism spectrum disorder diagnosis is made is unrelated to neonatal magnesium or the other covariates, the relative risks from the generalized estimating equations analysis can be interpreted as closely approximating the relative risks relating autism spectrum disorder to neonatal magnesium.^[@bibr21-2329048X18800566]^ Models were adjusted for potential confounders including infant sex, birth weight, gestational age, race/ethnicity, 5-minute Apgar score, maternal magnesium administration, maternal diabetes mellitus and gestational diabetes, and Medicaid insurance. To estimate subgroup-specific associations, the model was further stratified by early preterm birth (≤32 weeks' gestation) and exposure to antenatal maternal magnesium administration.

To explore how neonatal magnesium levels varied across gestational age at delivery among mothers who did and did not receive antenatal magnesium supplementation, a 3-way analysis of variance (ANOVA) including the 3-way interaction term was used to test for mean differences in magnesium levels by gestational age, autism spectrum disorder case status, and presence or absence of antenatal magnesium administration. For the ANOVA, gestational age for all weeks other than 36 weeks was binned into 2-week groups (eg, 22-23, 24-25 weeks, etc) due to low numbers of autism spectrum disorder cases by individual gestational age weeks (eg, no children with autism spectrum disorder were 22 or 24 weeks' gestational age at birth).

Study approvals were obtained from the Utah Registry of Autism and Developmental Disabilities Oversight Committee, University of Utah Institutional Review Board, Intermountain Healthcare Institutional Review Board, Utah State Board of Education Institutional Review Board, and Utah Department of Health Institutional Review Board. All analyses were conducted in SAS version 9.4 (SAS Institute Inc, Cary, North Carolina); an α of .05 was selected to assess statistical significance.

Results {#section6-2329048X18800566}
=======

Between 2002 and 2010, there were a total of 6437 preterm births at an Intermountain Healthcare facility in Utah who met the inclusion and exclusion criteria (see "Methods"). In all, 1582 patients had no birthweight record, magnesium level in the first 48 hours of life, or had died prior to determination of autism spectrum disorder status; the final study cohort consisted of 4855 preterm infants ([Figure 1](#fig1-2329048X18800566){ref-type="fig"}). One hundred twelve children in this cohort were classified with autism spectrum disorder (2.3%) between 2004 and 2014. The following differences were observed between children with and without autism spectrum disorder: proportion of males (77% vs 55%, *P* \< .0001), median gestational age (32 vs 33 weeks, *P* = .008), median birthweight (1685 vs 1990 g, *P* = .001), and median 5-minute Apgar score (8 vs 9, *P* = .009; [Table 1](#table1-2329048X18800566){ref-type="table"}).

![Flow diagram depicting identification of the final study cohort.](10.1177_2329048X18800566-fig1){#fig1-2329048X18800566}

###### 

Characteristics of Children With and Without Autism Spectrum Disorder.

![](10.1177_2329048X18800566-table1)

  Characteristic                        Unaffected (N = 4743)       Autism Spectrum Disorder cases (N = 112)   *P*               
  ------------------------------------- --------------------------- ------------------------------------------ --------- ------- ------------
  Median serum magnesium, mg/dL (IQR)   1.80 (1.60-2.30)            1.90 (1.70-2.50)                           .29^a^            
  Male                                  2676                        (56.4%)                                    86        (77%)   \<.0001^b^
  Median gestational age, weeks (IQR)   33.00 (30.00-35.00)         32.00 (27.50-35.00)                        .008^a^           
  Median birthweight, g, (IQR)          1990.00 (1503.00-2435.00)   1685.50 (1030.50-2433.00)                  .001^a^           
  Median 5 minute Apgar score, (IQR)    9 (8-9)                     8 (7-9)                                    .009^a^           
  Size for gestational age                                                                                                       .18^b^
   Small for gestational age            704                         (14.8%)                                    19        (17%)   
   Average for gestational age          3910                        82.5%                                      93        83%     
   Large for gestational age            129                         2.7%                                       0         0%      
  Race/ethnicity^c^                                                                                                              .43^b^
   White                                3819                        84.3%                                      95        89%     
   Hispanic                             531                         11.7%                                      9         9%      
   Other                                187                         4%                                         3         3%      
  Antenatal magnesium administration    1558                        32.9%                                      39        35%     .66^b^
  Medicaid insurance                    1533                        32.3%                                      33        30%     .52^b^
  Diabetes^d^                           423                         8.9%                                       13        12%     .33^b^

Abbreviation: IQR, interquartile range.

^a^ Wilcoxon signed-rank test *P* value.

^b^ χ^2^ test *P* value.

^c^ Number with missing data = 211.

^d^ Includes diabetes mellitus and gestational diabetes.

The relative risk ratio of autism spectrum disorder associated with each 1 mg/dL increase in neonatal magnesium level was 1.15 (95% confidence interval: 0.91-1.39, *P* = .29; [Table 2](#table2-2329048X18800566){ref-type="table"}). The null relationship between neonatal magnesium level and autism spectrum disorder risk was robust to adjustment by potential confounders (relative risk =1.15; 95% confidence interval: 0.86-1.53, *P* = .36) and by subgroup stratification by early preterm birth or presence of maternal antenatal magnesium administration. The risk of autism spectrum disorder associated with neonate magnesium level among early and late preterm birth was 1.20 (95% confidence interval: 0.87-1.64, *P* = .26) and 0.91 (95% confidence interval: 0.48-1.74, *P* = .78), respectively. The risk of autism spectrum disorder associated with neonate magnesium level among mothers with and without antenatal magnesium administration was 1.21 (95% confidence interval: 0.87-1.68; *P* = .26) and 0.83 (95% confidence interval: 0.41-1.68; *P* = .61), respectively.

###### 

Adjusted Relative Risk of Autism Spectrum Disorder Associated With Neonatal Serum Magnesium Levels From a Multivariable Discrete Proportional Hazard Regression Model.

![](10.1177_2329048X18800566-table2)

  Variable                             RR (95% CI)        *P*
  ------------------------------------ ------------------ ---------
  Serum magnesium, mg/dL               1.15 (0.86-1.53)   .36
  Male                                 2.81 (1.78-4.44)   \<.0001
  5-minute Apgar score                 0.96 (0.86-1.07)   .45
  Birthweight, g                       0.75 (0.51-1.09)   .13
  Gestational age, weeks               0.97 (0.88-1.06)   .49
  Race/ethnicity                                          
   White                               Reference          
   Hispanic                            0.60 (0.28-1.31)   .20
   Other                               0.62 (0.20-1.99)   .43
  Antenatal magnesium administration   0.79 (0.47-1.34)   .38
  Medicaid insurance                   0.94 (0.59-1.50)   .79
  Diabetes^a^                          1.24 (0.68-2.25)   .49

Abbreviations: CI, confidence interval; RR, relative risk.

^a^ Includes diabetes mellitus and gestational diabetes.

[Figure 2](#fig2-2329048X18800566){ref-type="fig"} displays mean (±standard error) magnesium levels among preterm infants across gestational age by autism spectrum disorder status (yes vs no) and stratified by the presence or absence of antenatal maternal magnesium supplementation. The 3-way ANOVA (*F* ~30,4824~ = 148.28, *P* \< .0001) demonstrated mean differences in magnesium levels by gestational age (*F* ~7,4824~ = 3.13, *P* = .0027) and maternal antenatal magnesium supplementation, but not autism spectrum disorder case status (mean \[standard deviation\] = 2.23 \[0.95\] among autism spectrum disorder cases vs mean \[standard deviation\] = 2.15 \[0.83\] among non-autism spectrum disorder--affected neonates (*F* ~1,4824~ = 1.43, *P* = .23)). Higher mean magnesium levels were associated with the presence versus absence of antenatal magnesium administration (mean \[standard deviation\] = 2.97 \[0.97\] vs 1.75 \[0.30\]; *F* ~1,4824~ = 287.78, *P* \< .0001, respectively). While the gestational age by autism spectrum disorder case status (*F* ~7,4824~ = 1.67, *P* = .11) and the antenatal magnesium administration by autism spectrum disorder case status (*F* ~1,4824~ = 3.02, *P* = .08) interactions were not statistically significant, the interaction between gestational age and antenatal magnesium administration was statistically significant (*F* ~7,4824~ = 2.55, *P* = .01). Finally, the 3-way interaction between gestational age, antenatal magnesium supplementation, and autism spectrum disorder case status was not statistically significant (*F* ~6,4824~ = 1.79, *P* = .10).

![Mean magnesium levels (±standard error) across gestational age among children with and without autism spectrum disorder and stratified by the presence or absence of antenatal magnesium supplementation (top and bottom panels, respectively).](10.1177_2329048X18800566-fig2){#fig2-2329048X18800566}

Discussion {#section7-2329048X18800566}
==========

To our knowledge, this is the first study to examine for the association between neonatal magnesium levels and autism spectrum disorder risk. We hypothesized a protective relationship between higher neonatal magnesium levels and lower autism spectrum disorder risk based on the well-supported yet modest association found between antenatal magnesium administration and reduced cerebral palsy risk.^[@bibr12-2329048X18800566],[@bibr22-2329048X18800566]^ However, our study did not find a statistically significant association. Further, our null finding was robust to stratification by early preterm birth and exposure to maternal antenatal magnesium supplementation. In contrast, complementary studies investigating the association between neonatal magnesium levels and cerebral palsy risk have yielded mixed results (Doll et al, 2014).^[@bibr21-2329048X18800566]^ Doll et al^[@bibr20-2329048X18800566]^ reported an inverse relationship between higher average serum magnesium levels and motor functioning measured at 20 to 36 months of age among 75 preterm infants. Conversely, Ostrander et al^[@bibr21-2329048X18800566]^ did not find a protective effect of magnesium levels drawn between 24 and 48 hours of life on risk of developing epilepsy or motor impairment in a large cohort of preterm Utah births. However, it is notable that Ostrander et al also did not find a reduction in cerebral palsy from maternal magnesium administration. This suggests that the efficacy of magnesium on outcomes may be tempered by an unrecognized effect, for example, socioeconomic or genetic background of the study population.

Mechanisms that may impart magnesium's neuroprotective effects for cerebral palsy could also be relevant to the pathophysiological origins of autism spectrum disorder. Magnesium may have multiple effects, including preventing axon pathfinding errors^[@bibr23-2329048X18800566]^ and limiting neuronal injury from hypoxic events and inflammation by reducing glutamate excitotoxicity and neuronal cell death.^[@bibr28-2329048X18800566]^ Further, cerebral palsy and autism spectrum disorder could be caused by separate mechanisms. Even if cerebral palsy and autism spectrum disorder share common pathophysiological features, our study suggest that cerebral palsy risk is more amenable than autism spectrum disorder risk to antenatal magnesium administration. Finally, differences in timing or mechanism of neuronal injury leading to cerebral palsy or autism spectrum disorder would then affect the timing and effectiveness of magnesium administration.

Only 1% of the body's magnesium is extracellular, plasma levels are determined by renal functioning, and homeostatic magnesium load remains constant during pregnancy.^[@bibr16-2329048X18800566]^ While the current study is consistent with previous studies that demonstrate how neonatal magnesium levels decline with advancing gestational age among neonates not exposed to antenatal maternal magnesium supplementation,^[@bibr16-2329048X18800566][@bibr17-2329048X18800566][@bibr18-2329048X18800566]--[@bibr19-2329048X18800566]^ findings also suggest that the same pattern exists among neonates exposed to antenatal maternal magnesium supplementation. Interestingly, although not significant, we did note that in infants of early preterm birth, compared to late preterm/near-term birth, that for infants exposed to antenatal maternal magnesium supplementation, infants who subsequently developed an autism spectrum disorder had higher serum magnesium levels. Thus, future studies may need to take into consideration the gestational age of the infant, for example, considering potential differences in magnesium stores or metabolism based on gestational age.

Our analysis was limited to neonatal magnesium levels drawn 24 to 48 hours following birth to reduce the influence of antenatal magnesium administration; however, our results clearly demonstrate that antenatal magnesium administration impacts the neonate's plasma magnesium levels during this time. Elevated magnesium levels in neonates resulting from antenatal maternal magnesium administration have been shown to fall significantly during the first 48 hours after birth, but do remain elevated through at least the first 72 hours of life.^[@bibr29-2329048X18800566]^ It is unclear whether antenatal magnesium exposure impacts the neonate's magnesium homeostatic load beyond elevation in the peripheral circulation.

A meta-analysis conclusively established the association between antenatal magnesium administration and reduced cerebral palsy risk, though the effect size was small.^[@bibr12-2329048X18800566]^ If a protective effect of neonatal magnesium levels on autism spectrum disorder risk was of similar magnitude, limitations inherent to this study cohort could mask detection. For example, with a mean elevation of 6100 ft,^[@bibr30-2329048X18800566]^ Utah has the third highest average elevation in the United States. Higher elevations are implicated in obstetrical complications related to prematurity (ie, low birth weight, gestational hypertension, preeclampsia)^[@bibr31-2329048X18800566],[@bibr32-2329048X18800566]^ and may negate a modest protective effect against neuronal injury from inflammation or hypoxia. This is consistent with a previously published study from our group that also failed to show a protective effect of magnesium on cerebral palsy risk related to either antenatal magnesium administration or neonatal magnesium levels.^[@bibr21-2329048X18800566]^ Utah's relative homogeneity in racial/ethnic composition also limits this cohort's genetic variability. Homeostatic levels of magnesium are genetically determined by several gene polymorphisms,^[@bibr33-2329048X18800566]^ and subgroup analysis of neonatal outcomes associated with antenatal maternal magnesium administration supports differential effects across racial groups.^[@bibr34-2329048X18800566]^ Subsequently, further study of neonatal magnesium and autism spectrum disorder risk among more diverse groups located at sea level might yield different findings. Study limitations also include the use of autism spectrum disorder classification as a dichotomous outcome variable. Use of a continuous measure of social communication ability would better reflect the autism spectrum disorder spectrum and improve the study's power to detect a small effect size.

Study strengths include the use of a retrospective cohort design and high autism spectrum disorder capture rate (2.3%). Utah Registry of Autism and Developmental Disabilities uses both medical and education sources to identify children with autism spectrum disorder, thereby providing thorough autism spectrum disorder ascertainment. Pre-/perinatal risk factors were also ascertained using maternal and neonatal medical records rather than birth certificate records. Medical records exceed birth certificates in accuracy and thoroughness for maternal and neonatal medical interventions and complications.^[@bibr35-2329048X18800566][@bibr36-2329048X18800566]--[@bibr37-2329048X18800566]^

Ideally, we would have available a series of serum magnesium levels at equal intervals in the premature infant, which we could examine for their relationship to the risk for autism spectrum disorder. However, because there was only the reliable presence of serum magnesium levels in the first several days of life, our study had to be constrained to the available data. Further, because the magnesium level in the first 24 hours of life corresponded precisely with whether antenatal magnesium supplementation was performed, these 2 factors (magnesium level in the first 24 hours of life and maternal magnesium supplementation) acted essentially as a single variable. For this reason, we only considered the variable of maternal magnesium supplementation.

Our findings suggest a null association between magnesium levels in preterm infants during their second day of life and autism spectrum disorder. However, animal models and human studies demonstrate magnesium's neuroprotective effects for cerebral palsy,^[@bibr12-2329048X18800566],[@bibr22-2329048X18800566],[@bibr28-2329048X18800566]^ which support continued efforts to identify key biochemical and genetic targets of magnesium action in premature infants. Additional studies into the fundamental genetic and biochemical mechanisms associated with the adverse effects of prematurity could also identify other molecular targets. Future studies can enhance our understanding of magnesium's potential influence on fetal and neonatal brain development in the context of autism spectrum disorder by including a larger, more racially/ethnically diverse sample, implementing a continuous, quantitative measure of social communication ability to assess autism spectrum disorder phenotype, and investigating this relationship in a cohort born at lower elevation.
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